Lannacheng Biotech Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
12
Lannacheng Biotech General Information
Description
Developer of oncological nuclear medicine platform designed for cancer treatment. The company focuses on building a global platform for innovative nuclear medicine for the diagnosis and treatment of various types of cancer, providing the healthcare and oncology sectors with comprehensive, innovative solutions for cancer care.
Contact Information
Website
www.dc-lnc.comCorporate Office
- Room 101, Building 52, Number 500, Binhai East Road
- Muping District
- Yantai, Shandong 264100
- China
Corporate Office
- Room 101, Building 52, Number 500, Binhai East Road
- Muping District
- Yantai, Shandong 264100
- China
Lannacheng Biotech Timeline
Lannacheng Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. IPO | 13-Oct-2026 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series C1) | 18-Jul-2025 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 14-Feb-2025 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B1) | 24-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 27-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series B) | 23-Jun-2023 | $28.1M | $28.1M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 01-Jun-2022 | Completed | Startup |
Lannacheng Biotech Patents
Lannacheng Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022170732-A1 | Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof | Inactive | 10-Feb-2021 |
Lannacheng Biotech Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| China Cinda Asset Management | Corporation | Minority | ||
| Inner Mongolia New Energy Investment Funds Management | Government | Minority | ||
| Shanghai Rui Investment Fund Management | Asset Manager | Minority | ||
| Qianhai FoF | Fund of Funds | Minority | ||
| Shenzhen Capital Group | Venture Capital | Minority |
Lannacheng Biotech FAQs
-
When was Lannacheng Biotech founded?
Lannacheng Biotech was founded in 2021.
-
Where is Lannacheng Biotech headquartered?
Lannacheng Biotech is headquartered in Yantai, China.
-
What industry is Lannacheng Biotech in?
Lannacheng Biotech’s primary industry is Drug Discovery.
-
Is Lannacheng Biotech a private or public company?
Lannacheng Biotech is a Private company.
-
What is Lannacheng Biotech’s current revenue?
The current revenue for Lannacheng Biotech is .
-
How much funding has Lannacheng Biotech raised over time?
Lannacheng Biotech has raised $132M.
-
Who are Lannacheng Biotech’s investors?
China Cinda Asset Management, Inner Mongolia New Energy Investment Funds Management, Shanghai Rui Investment Fund Management, Qianhai FoF, and Shenzhen Capital Group are 5 of 12 investors who have invested in Lannacheng Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process